Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DC therapy for prostate cancer.

P W Swindle1, S Tepes, J Clements

  • 1Mater Prostate Cancer Research Centre, Mater Medical Research Institute, Queensland, South Brisbane, Australia.

Cytotherapy
|June 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prehabilitation in the prison population.

Anaesthesia reports·2024
Same author

Recent advancements and application of in vitro models for predicting inhalation toxicity in humans.

Toxicology in vitro : an international journal published in association with BIBRA·2021
Same author

Facing the Ethical Challenges: Consumer Involvement in COVID-19 Pandemic Research.

Journal of bioethical inquiry·2020
Same author

An experimental aerosol air-agar interface mouse lymphoma assay methodology.

Mutation research. Genetic toxicology and environmental mutagenesis·2020
Same author

First Reports of Brown Fruit Rot on Sweet Cherry (Prunus avium) and Plum (P. domestica) and Shoot Blight on Apricot (P. armeniaca), Kwanzan Cherry (P. serrulata), and Sweet Cherry (P. avium) Caused by Monilinia laxa in New York, Rhode Island, and Massachusetts.

Plant disease·2019
Same author

Bone marrow-derived stem/stromal cells (BMSC) 3D microtissues cultured in BMP-2 supplemented osteogenic induction medium are prone to adipogenesis.

Cell and tissue research·2018
Same journal

Dialysis bioreactor enables high-density, serum-free expansion of dental pulp-derived mesenchymal stromal cells with enhanced secretome.

Cytotherapy·2026
Same journal

Beyond the synapses: should we anticipate neurotransmitter signaling when manufacturing CAR-T cells for brain tumors?

Cytotherapy·2026
Same journal

Curative treatment for severe sickle cell disease: allogeneic hematopoietic cell transplant or gene therapy.

Cytotherapy·2026
Same journal

Manufacturing strategies for prolonged CAR-T cell persistence.

Cytotherapy·2026
Same journal

Overcoming five main challenges to targeting hematologic malignancies.

Cytotherapy·2026
Same journal

Mesenchymal stromal cell-based therapy in the COVID-19 pandemic: results from an academic phase I/II double-blind, randomized, placebo-controlled clinical trial and reflections for the field.

Cytotherapy·2026
See all related articles

Current prostate cancer treatments offer limited survival benefits. Harnessing the immune system, specifically with dendritic cell (DC) therapies, shows potential for cancer cell destruction but has not yet improved overall survival in metastatic prostate cancer.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Metastatic prostate cancer treatments provide modest palliative effects without improving overall survival.
  • The immune system can be modulated to target and destroy cancer cells.
  • Harnessing immune responses, like those seen in transplant rejection, offers potential for tumor treatment.

Purpose of the Study:

  • To review the current state of dendritic cell (DC) immunotherapy for prostate cancer.
  • To evaluate the efficacy of DC therapies in metastatic prostate cancer.
  • To explore the potential of immune system modulation in prostate cancer treatment.

Main Methods:

  • Review of existing clinical data on DC immunotherapy for prostate cancer.
  • Analysis of studies investigating immune responses against prostate tumors.

Related Experiment Videos

  • Assessment of the impact of DC therapies on patient outcomes.

    • Main Results:

    • Modest clinical responses observed in metastatic prostate cancer patients treated with DC therapies.
    • No significant increase in overall survival demonstrated with current DC immunotherapy approaches.
    • The review highlights the current limitations and potential of DC-based treatments.

    Conclusions:

    • Dendritic cell (DC) immunotherapy shows promise for treating metastatic prostate cancer by engaging the immune system.
    • Despite modest clinical responses, current DC therapies have not yet translated into improved overall survival.
    • Further research and development are needed to optimize DC immunotherapy for enhanced efficacy in prostate cancer.